Management of prostate-specific antigen relapse in prostate cancer: A European consensus
- 29 April 2004
- journal article
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 58 (4) , 382-390
Abstract
A European Consensus on the management of prostate-specific antigen (PSA) relapse in patients with prostate cancer has been formulated. The key recommendations proposed are that total PSA is the best detection tool for prostate cancer, with free and complexed PSA having a role in the PSA range 1–4 ng/ml. PSA relapse after radical prostatectomy (RP) has been defined as a value of 0.2 ng/ml with one subsequent rise, while the ASTRO definition should be used after radiotherapy. A PSA level of less than 0.4 ng/ml after hormonal therapy can be considered an indicator of a positive response. Continuous assessment using nomograms or artificial neural networks will help to determine whether progression after local therapy is distant or local, which is the basis for treatment decisions. Secondary treatment after local failure of RP should be initiated when PSA levels reach 1.0–1.5 ng/ml and salvage radiotherapy can be considered with or without hormonal therapy. Local failure after radiotherapy can be treated with a choice of high-intensity-focused ultrasound, salvage RP (only in highly selected patients), cryotherapy or external beam radiation. Treatment of distant failure involves hormonal manipulation, the type and the timing of which is based on both physician and patient preferences.Keywords
This publication has 65 references indexed in Scilit:
- A competing‐risks nomogram for sarcoma‐specific death following local recurrenceStatistics in Medicine, 2003
- Robustness of Free Prostate Specific Antigen Measurements to Reduce Unnecessary Biopsies in the 2.6 to 4.0 ng./ml. RangeJournal of Urology, 2002
- Strategies Combining Total and Percent Free Prostate Specific Antigen for Detecting Prostate Cancer: A Prospective EvaluationJournal of Urology, 2002
- Osteoporosis in Men Treated With Androgen Deprivation Therapy for Prostate CancerJournal of Urology, 2002
- PROSTATE SPECIFIC ANTIGEN BOUNCE AFTER RADIOACTIVE SEED IMPLANTATION FOLLOWED BY EXTERNAL BEAM RADIATION FOR PROSTATE CANCERJournal of Urology, 2000
- Positron emission tomography with 18 fluorine‐labelled deoxyglucose: utility in localized and advanced prostate cancerBJU International, 1999
- Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate CancerNew England Journal of Medicine, 1999
- PROSTATE SPECIFIC ANTIGEN NADIR ACHIEVED BY MEN APPARENTLY CURED OF PROSTATE CANCER BY RADIOTHERAPYJournal of Urology, 1999
- A Multivariate Analysis of Clinical and Pathological Factors that Predict for Prostate Specific Antigen Failure after Radical Prostatectomy for Prostate CancerJournal of Urology, 1995
- Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volumeCancer, 1993